Acquired inhibitors of coagulation are antibodies that either inhibit the activity or increase the clearance of a clotting factor.
●Some disorders may be associated with antibodies to a variety of clotting factors. In systemic lupus erythematosus, for example, antiphospholipid antibodies and antibodies directed against factors II, VIII, IX, XI, XII, and XIII have been described . (See "Hematologic manifestations of systemic lupus erythematosus in adults", section on 'Antibodies to clotting factors and phospholipids' and "Clinical manifestations of the antiphospholipid syndrome", section on 'Other antiphospholipid antibodies'.)
●Antiphospholipid antibodies represent a special problem; these antibodies prolong certain clotting assays, but result in thrombosis rather than bleeding. The pathogenesis, diagnosis, and treatment of conditions associated with antiphospholipid antibodies are discussed elsewhere in UpToDate. (See "Pathogenesis of the antiphospholipid syndrome" and "Clinical manifestations of the antiphospholipid syndrome" and "Treatment of the antiphospholipid syndrome".)
A common clinical manifestation in affected patients is a hemorrhagic diathesis. Acquired coagulation inhibitors that lead to bleeding will be reviewed here. The natural history and management of these inhibitors are quite different from inhibition due to alloantibodies that occur in patients with various inherited bleeding disorders (eg, congenital deficiencies of factors VIII, IX, or XI) treated with factor replacement. The latter problem is discussed separately. (See "Factor VIII and factor IX inhibitors in patients with hemophilia" and "Factor XI deficiency", section on 'FXI inhibitors'.)
FACTOR VIII INHIBITORS
The most common autoantibodies that affect clotting factor activity and lead to a bleeding disorder are directed against, and interfere with, the activity of factor VIII, a condition also called acquired hemophilia A [2-5]. Although there are no large series describing the immunoglobulin class of the factor VIII autoantibodies, most have been IgG antibodies that do not bind complement.